^
    Back
    Association details:
    Biomarker:PTPN11 mutation
    Cancer:Acute Myelogenous Leukemia
    Drug:cytarabine (DNA synthesis inhibitor, DNA-directed DNAP inhibitor) +
    daunorubicin (Topoisomerase II inhibitor, DNA intercalator) +
    mitoxantrone (Topoisomerase II inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASH 2020
    Title:

    PTPN11 mutations and Outcomes in Adult Patients with Acute Myeloid Leukemia

    Published date:
    11/04/2020
    Excerpt:
    All patients had received induction chemotherapy containing cytarabine and daunorubicin or mitoxantrone....In univariate analyses, PTPN11-mutated patients had significantly longer relapse-free survival (RFS; 5-year estimate, 55% vs 33% for PTPN11-wild type patients; P=.001...and tended to have longer overall survival (OS; 5-year estimate, 43% vs 32%; P=.06...
    DOI:
    https://doi.org/10.1182/blood-2020-137487